journal
Journals Expert Review of Anticancer Th...

Expert Review of Anticancer Therapy

https://read.qxmd.com/read/38366359/development-and-validation-of-survival-nomograms-in-elder-triple-negative-invasive-ductal-breast-carcinoma-patients
#1
JOURNAL ARTICLE
Tao Jiang, Sha Yang, Guanghui Wang, Ying Tan, Shu Liu
BACKGROUND: We aimed to develop a nomogram to predict the overall survival of elderly patients with Triple-negative invasive ductal breast carcinoma (TNIDC). RESEARCH DESIGN AND METHODS: 12165 elderly patients with nonmetastatic TNIDC were retrieved from the SEER database from 2010 to 2019 and were randomly assigned to training and validation cohorts. Stepwise Cox regression analysis was used to select variables for the nomogram based on the training cohort. Univariate and multivariate Cox analyses were used to calculate the correlation between variables and prognosis of the patients...
February 16, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38362755/exploiting-c-raf-dependency-in-ras-mutant-cancer-beyond-catalytic-activity
#2
EDITORIAL
Sean F Cooke, Connor M Blair
No abstract text is available yet for this article.
February 16, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38299537/the-assessment-of-circulating-tumor-dna-associated-with-wnt-%C3%AE-catenin-signaling-pathway-as-a-diagnostic-tool-for-liver-cancer-a-systematic-review-and-meta-analysis
#3
REVIEW
Xingyuan Ma, Zhe Wang, Shuaiyang Wang, Ye Tian, Bei Xie, Jing Li, Bin Ma, Linjing Li
BACKGROUND: Circulating tumor DNA (ctDNA) in peripheral blood has become a promising noninvasive biomarker. However, the diagnostic potential of Wnt/β-catenin signaling pathway-related ctDNA for liver cancer is controversial. Here, we aimed to access the diagnostic potential and clinicopathological features of Wnt/β-catenin signaling pathway-related ctDNA in liver cancer and provide data support for its clinical diagnosis and treatment. METHODS: A comprehensive literature search was conducted to identify the relevant studies...
February 1, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38288663/cancer-immunotherapy-efficacy-and-machine-learning
#4
REVIEW
Yuting Fang, Xiaozhong Chen, Caineng Cao
INTRODUCTION: Immunotherapy is one of the major breakthroughs in the treatment of cancer and it has become a powerful clinical strategy, however, not all patients respond to immune checkpoint blockade and other immunotherapy strategies. Applying machine learning (ML) techniques to predict the efficacy of cancer immunotherapy is useful for clinical decision-making. AREAS COVERED: Applying ML including deep learning (DL) in radiomics, pathomics, tumor microenvironment (TME) and immune-related genes analysis to predict immunotherapy efficacy...
January 30, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38252024/safety-and-efficacy-of-rucaparib-in-the-treatment-of-ovarian-cancer-and-patients-with-brca-mutation-a-systematic-review-and-meta-analysis-of-phase-iii-randomized-clinical-trials
#5
REVIEW
Mus'ab Theeb Mustafa, Aws Khalid Abushanab, Mahmoud Taysir Mousa, Rana Ahmed Qawaqzeh, Hamza Muneer Alakhras, Ahmad Sami Othman, Ahmad Sa'ed
INTRODUCTION: Our systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of Rucaparib, a PARP inhibitor (PARPi), in patients with ovarian cancer and BRCA mutation. METHODS: Online databases were comprehensively searched for all phase III Randomized trials that used Rucaparib therapy for ovarian cancer patients and patients having BRCA mutation. Efficacy results are progression-free survival and overall response rate in addition to addressing its safety concerns...
January 22, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38230741/considerations-regarding-maintenance-therapy-for-acute-myeloid-leukemia-in-remission
#6
JOURNAL ARTICLE
Gary J Schiller, Vlad Kustanovich
INTRODUCTION: For most adult patients with acute myeloid leukemia, relapse is characteristic of the disease. When allotransplant in first complete remission is administered as consolidative therapy, relapse is still common, affecting 20-40% of recipients. Maintenance of remission with low-dose treatments may hold promise in preventing relapse. AREAS COVERED: Improvements in the detection of clinical and biologic variants of disease allow the practitioner to identify which patients, based on disease features, may benefit from therapy directed at residual clonal elements that might contribute to relapse...
January 17, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38230690/lncrna-hcg11-enhances-the-chemosensitivity-of-non-small-cell-lung-cancer-cells-to-gemcitabine-via-mir-17-5p-p21-axis
#7
JOURNAL ARTICLE
Yufen Xu, Xiaoli Tan, Qi Yang, Zhixian Fang, Wenyu Chen
BACKGROUND: This study investigated the inhibitory effects of lncRNA HLA Complex Group 11 (HCG11) on non-small cell lung cancer (NSCLC) and the molecular mechanisms. RESEARCH DESIGN AND METHODS: Bioinformatics analysis was conducted to determine the downstream targeted gene miR-17-5p/p21 and predict their binding sites. qRT-PCR and Western blot were used to detect expression levels, and dual luciferase and RIP assays were adopted to verify binding relationship. RESULTS: The lncRNA HCG11/miR-17-5p/p21 axis was found to regulate drug resistance, proliferation, apoptosis, and cell cycle of A549 and A549-Gemcitabine (GEM) cells...
January 17, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38224371/allogeneic-transplantation-and-cellular-therapies-in-cutaneous-t-cell-lymphoma
#8
REVIEW
Amrita Goyal, Francine Foss
INTRODUCTION: Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell lymphoma. Although many available treatments offer temporary disease control, allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only curative treatment option for advanced stage MF and SS. CAR T-cell therapy is a promising new avenue for treatment. AREAS COVERED: In this review, we discuss the evidence supporting the use of allo-HSCT for the treatment of MF/SS, including disease status at the time of transplant, conditioning regimen, total body irradiation (TBI), and donor lymphocyte infusion (DLI)...
January 15, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38174379/comparison-of-poly-adp-ribose-polymerase-inhibitors-parpis-as-maintenance-therapy-for-newly-diagnosed-and-platinum-sensitive-recurrent-ovarian-cancer-with-brca-mutational-status-a-systematic-review-and-network-meta-analysis
#9
REVIEW
Shulin Zhou, Yi Jiang, Chengyan Luo, Lin Yuan
BACKGROUND: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) treatment for ovarian cancer (OC) are ever-changing. This study aimed to compare the efficacy and overall safety of available PARPi as maintenance therapy for BRCA mutation status in patients with newly diagnosed and platinum-sensitive recurrent (PSR) OC patients. RESEARCH DESIGN AND METHODS: Relevant RCTs were systematically retrieved from PubMed and Embase until 31 May 2022. Progression-free survival (PFS) and overall survival (OS) based on BRCA mutation status and adverse events (AEs) regardless of mutation were efficacy and safety endpoints...
January 4, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38127132/circadian-rhythm-based-cancer-therapy-in-randomized-clinical-trials
#10
REVIEW
Loredana G Marcu
INTRODUCTION: Since the 2017 Nobel prize awarded to J. Hall, M. Rosbash and M.W. Young for their discoveries of molecular mechanisms behind the biological clock, circadian rhythm-based therapy, also known as chronotherapy, is receiving more attention in oncology and the number of anatomical sites of interest in this field is increasing. This observation is in line with the clinical evidence provided by trials on head and neck, lung, colorectal and cervical cancers, as well as the presently ongoing chronotherapy trials for breast and brain cancers...
December 21, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38044867/prognostic-significance-of-dickkopf-1-in-head-and-neck-squamous-cell-carcinoma
#11
REVIEW
Kai Chen, Jin Li, Yanfeng Ouyang, Yulong Xie, Guiqiong Xu, Tianliang Xia, Rui You, Guichao Liu, Han He, Rong Huang, Mingyuan Chen
BACKGROUND: Dickkopf-1 (DKK1) exhibits abnormal expression in various cancers and correlates with poor prognosis. This study investigates DKK1's prognostic relevance in head and neck squamous cell carcinoma (HNSC). METHODS: We conducted a comprehensive search across literature and sequencing databases to gather eligible studies and HNSC datasets. We calculated pooled standardized mean differences (SMD) and 95% confidence intervals (CI) for clinical characteristics, as well as hazard ratios (HR) with 95% CIs for overall survival (OS) and progression-free/disease-free survival (PFS/DFS)...
December 4, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38032181/medical-imaging-and-multimodal-artificial-intelligence-models-for-streamlining-and-enhancing-cancer-care-opportunities-and-challenges
#12
REVIEW
Kevin Pierre, Manas Gupta, Abheek Raviprasad, Seyedeh Mehrsa Sadat Razavi, Anjali Patel, Keith Peters, Bruno Hochhegger, Anthony Mancuso, Reza Forghani
INTRODUCTION: Artificial intelligence (AI) has the potential to transform oncologic care. There have been significant developments in AI applications in medical imaging and increasing interest in multimodal models. These are likely to enable improved oncologic care through more precise diagnosis, increasingly in a more personalized and less invasive manner. In this review, we provide an overview of the current state and challenges that clinicians, administrative personnel and policy makers need to be aware of and mitigate for the technology to reach its full potential...
November 30, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38031874/ifosfamide-induced-nephrotoxicity-in-oncological-patients
#13
JOURNAL ARTICLE
Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vasquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérrez, Luis Alberto Concepción-Urteaga, Juan Carlos Haro-Varas, Marcio José Concepción-Zavaleta
INTRODUCTION: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. AREAS COVERED: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells...
November 30, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38014557/fixed-duration-therapy-comes-of-age-in-cll-long-term-results-of-murano-and-cll14-trials
#14
JOURNAL ARTICLE
Stefano Molica, David Allsup
INTRODUCTION: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials. AREA COVERED: This article delves into the long-term follow-up data of fixed duration (FD) venetoclax combined with anti-CD20 mAb across various lines of CLL therapy. The data discussed here, not yet available in current literature, was unveiled at the 23rd European Hematological Association (EHA) congress held in Frankfurt in June 2023...
November 28, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/37994866/nectin-4-targeted-theranostics-for-urothelial-cancer-getting-ready-for-primetime
#15
REVIEW
Luca Filippi, Orazio Schillaci
Locally advanced and metastatic urothelial carcinoma (UC) presents a bleak prognosis, with limited treatment options. NECTIN-4, an overexpressed protein in UC, has become a target for therapy. Enfortumab vedotin (EV) gained Food and Drug Administration approval for advanced UC treatment, but patient selection based on NECTIN-4 expression remains challenging. In the study under evaluation, Duan et al. introduced a novel PET/CT imaging approach using 68 Ga-N188, a molecular probe, to visualize NECTIN-4 expression in UC...
November 23, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/37950424/efficacy-and-toxicity-of-drugs-targeting-kras-g12c-mutation-in-non-small-cell-lung-cancer-a-meta-analysis
#16
REVIEW
Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke Xu
OBJECTIVE: To systematically analyze the efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer (NSCLC). METHODS: The candidate studies were identified in PubMed, Embase, Cochrane Library, CNKI and Wanfang databases up to 1 June 2023. Data on efficacy, prognosis, and adverse events (AEs) were extracted and calculated by meta-analysis. RESULTS: Six eligible prospective studies were included in this meta-analysis, including 563 patients with advanced or metastatic NSCLC...
November 10, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/37934874/prognostic-value-of-circulating-long-non-coding-rnas-in-colorectal-cancer-patients-a-meta-analysis
#17
REVIEW
Bin Hu, Yanfei Zhang, Bingjing Jiang, Angcheng Li
OBJECTIVES: This meta-analysis aimed to evaluate the prognostic significance of circulating long non-coding RNAs (lncRNAs) in colorectal cancer (CRC), focusing on their associations with disease-free survival (DFS), overall survival (OS), and clinicopathological features. METHODS: A comprehensive literature search was conducted in databases (Embase, Web of Science, PubMed, and Cochrane Library) up to July 2022 to identify studies investigating the prognostic value of circulating lncRNAs in CRC...
November 7, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/37908134/immune-checkpoint-inhibitors-in-advanced-cutaneous-melanoma-a-systematic-review-and-meta-analysis-of-efficacy-and-review-of-characteristics
#18
REVIEW
Sara Mahdiabadi, Sara Momtazmanesh, Amirali Karimi, Nima Rezaei
OBJECTIVES: Immune checkpoint inhibitors (ICIs) are one of the most promising approaches toward advanced melanoma. Here, we aimed to perform a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of all studied ICIs. METHODS: We conducted a comprehensive search to identify the relevant publications (PROSPERO registration ID: CRD42023470649). Then we performed a meta-analysis to evaluate the efficacy of different ICIs for metastatic melanoma...
October 31, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/37850939/association-between-event-free-survival-and-overall-survival-after-neoadjuvant-treatment-for-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#19
REVIEW
Gyula Ostoros, Robert Hettle, Nefeli Georgoulia, Mehmet Berktas, Pratibha Chander, Ignacio Diaz Perez, Anne-Marie Couto, Christian Eichinger, Polly Field, Peter Morten
BACKGROUND: We wanted to evaluate if event-free survival (EFS) is a reliable surrogate for overall survival (OS) in patients with resectable non-small cell lung cancer (r-NSCLC) receiving neoadjuvant therapy, we conducted a systematic literature review and meta-analysis to investigate the statistical association between EFS and OS. RESEARCH DESIGN AND METHODS: Electronic databases were searched on 30 July 2021 to identify sources reporting both EFS and OS data in patients with stage I - IIIB r-NSCLC receiving neoadjuvant therapy...
October 18, 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/37850259/the-role-of-nelarabine-in-the-treatment-of-t-cell-acute-lymphoblastic-leukemia-lymphoma-challenges-opportunities-and-future-directions
#20
REVIEW
Lane H Miller, Kim L Maxa, Stuart S Winter, Nathan P Gossai
INTRODUCTION: Nelarabine is a guanine nucleoside analog and functions to terminate DNA synthesis in dividing cells. Pre-clinical and clinical studies have shown that it preferentially accumulates in T-cells where it exerts its cytotoxic effects. After generations of treatment protocol advances, it has been incorporated into numerous treatment regimens against T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LLy). On 8 March 2023, the FDA approved the use of nelarabine for its use in T-ALL due to clear evidence of clinical benefits...
October 18, 2023: Expert Review of Anticancer Therapy
journal
journal
39793
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.